The cuts come amid a prolonged financial downturn for the gene-editing field, as valuations have plummeted and layoffs have become widespread. Editas already laid off staff as part of a restructuring in 2023. Its stock has fallen 81% this year.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
